Congress trading in JNJ
54 members of Congress have disclosed trading JNJ — 90 purchases and 49 sales worth an estimated $2.9M. Most recent disclosure: Dec 9, 2025.
See who in Congress traded JNJ →About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
JNJ Key Statistics
JNJ in plain English
- P/E ratio (29.5) — how many dollars you pay for each $1 of JNJ's yearly profit. That's a fairly normal range.
- ROE (26.42%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (21.83%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.10%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
Compare JNJ with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.